A Study of AMC6156 in People With Sarcopenia
A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AMC6156 in Patients With Sarcopenia
Animuscure Inc.
80 participants
Jul 1, 2025
INTERVENTIONAL
Conditions
Summary
This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral administration of AMC6156 in tablet form at a dose of 0.1 mg once daily for 12 weeks.
Oral administration of AMC6156 in tablet form at a dose of 0.3 mg once daily for 12 weeks.
Oral administration of AMC6156 in tablet form at a dose of 1.0 mg once daily for 12 weeks.
Oral administration of placebo tablets matching AMC6156 in appearance, once daily for 12 weeks.
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07072195